Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 2
1956 3
1966 1
1967 2
1968 3
1969 1
1970 1
1971 4
1973 2
1974 1
1975 1
1980 1
1981 6
1982 2
1983 3
1984 10
1985 6
1986 9
1987 23
1988 11
1989 8
1990 9
1991 6
1992 7
1993 12
1994 7
1995 13
1996 8
1997 19
1998 10
1999 7
2000 7
2001 15
2002 10
2003 14
2004 17
2005 15
2006 7
2007 15
2008 18
2009 22
2010 19
2011 16
2012 16
2013 15
2014 14
2015 19
2016 23
2017 15
2018 27
2019 21
2020 24
2021 42
2022 30
2023 22
2024 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

611 results

Results by year

Filters applied: . Clear all
Page 1
Mesenchymal Bmp3b expression maintains skeletal muscle integrity and decreases in age-related sarcopenia.
Uezumi A, Ikemoto-Uezumi M, Zhou H, Kurosawa T, Yoshimoto Y, Nakatani M, Hitachi K, Yamaguchi H, Wakatsuki S, Araki T, Morita M, Yamada H, Toyoda M, Kanazawa N, Nakazawa T, Hino J, Fukada SI, Tsuchida K. Uezumi A, et al. Among authors: kurosawa t. J Clin Invest. 2021 Jan 4;131(1):e139617. doi: 10.1172/JCI139617. J Clin Invest. 2021. PMID: 33170806 Free PMC article.
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, Yagi Y, Kurosawa T, Greener B, Zhang Y, Walson JL. Oda Y, et al. Among authors: kurosawa t. Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20. Lancet Infect Dis. 2024. PMID: 38141632 Clinical Trial.
Pneumocystis jirovecii pneumonia after CD4+ T-cell recovery subsequent to CD19-targeted chimeric antigen receptor T-cell therapy: A case report and brief review of literature.
Kawata K, Shima H, Shinjoh M, Yamazaki F, Kurosawa T, Yaginuma M, Takada H, Shimada H. Kawata K, et al. Among authors: kurosawa t. Cancer Rep (Hoboken). 2023 Oct;6(10):e1885. doi: 10.1002/cnr2.1885. Epub 2023 Aug 10. Cancer Rep (Hoboken). 2023. PMID: 37563749 Free PMC article. Review.
Congenital malignant melanoma.
Ishii N, Ichiyama S, Saito S, Kurosawa T, Nakajima H. Ishii N, et al. Among authors: kurosawa t. Br J Dermatol. 1991 May;124(5):492-4. doi: 10.1111/j.1365-2133.1991.tb00633.x. Br J Dermatol. 1991. PMID: 2039727 Review.
Relayed signaling between mesenchymal progenitors and muscle stem cells ensures adaptive stem cell response to increased mechanical load.
Kaneshige A, Kaji T, Zhang L, Saito H, Nakamura A, Kurosawa T, Ikemoto-Uezumi M, Tsujikawa K, Seno S, Hori M, Saito Y, Matozaki T, Maehara K, Ohkawa Y, Potente M, Watanabe S, Braun T, Uezumi A, Fukada SI. Kaneshige A, et al. Among authors: kurosawa t. Cell Stem Cell. 2022 Feb 3;29(2):265-280.e6. doi: 10.1016/j.stem.2021.11.003. Epub 2021 Dec 1. Cell Stem Cell. 2022. PMID: 34856120 Free article.
611 results